Publication

Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.

Journal Paper/Review - Mar 23, 2021

Units
PubMed
Doi
Contact

Citation
Engelter S, Traenka C, Gensicke H, Schaedelin S, Luft A, Simonetti B, Fischer U, Michel P, Sirimarco G, Kägi G, Vehoff J, Nedeltchev K, Kahles T, Kellert L, Rosenbaum S, von Rennenberg R, Sztajzel R, Leib S, Jung S, Gralla J, Bruni N, Seiffge D, Feil K, Polymeris A, Steiner L, Hamann J, Bonati L, Brehm A, De Marchis G, Peters N, Stippich C, Nolte C, Christensen H, Wegener S, Psychogios M, Arnold M, Lyrer P, TREAT-CAD investigators. Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial. Lancet Neurol 2021; 20:341-350.
Type
Journal Paper/Review (English)
Journal
Lancet Neurol 2021; 20
Publication Date
Mar 23, 2021
Issn Electronic
1474-4465
Pages
341-350
Brief description/objective

Cervical artery dissection is a major cause of stroke in young people (aged <50 years). Historically, clinicians have preferred using oral anticoagulation with vitamin K antagonists for patients with cervical artery dissection, although some current guidelines-based on available evidence from mostly observational studies-suggest using aspirin. If proven to be non-inferior to vitamin K antagonists, aspirin might be preferable, due to its ease of use and lower cost. We aimed to test the non-inferiority of aspirin to vitamin K antagonists in patients with cervical artery dissection.